January 29, 2010
Bioniche E. coli O157 Vaccine Recognized in Prestigious Scientific Journal

November 25, 2009
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Bioniche Life Sciences Inc. is a leading, fully-integrated biopharmaceutical company that discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide.

Media Coverage

For recent media coverage of Bioniche Life Sciences Inc. click here >>

Latest News

January 29, 2010
Bioniche E. coli O157 Vaccine Recognized in Prestigious Scientific Journal more...

November 25, 2009
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform more...

November 6, 2009
Bioniche Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under Licensing Agreement more...

More News

Bioniche Key Facts

Founded: 1979

Chairman, President & CEO:
Graeme McRae

TSX stock symbol:
BNC

Fiscal year-end:
June 30

2008 revenues:
C$27.7 million

Headquarters:
Belleville, Ontario

Employees worldwide:
200

Business divisions:
Human Health,
Animal Health,
Food Safety

Focus areas:
Human Health:
cancer, immunomodulation

Animal Health:
reproduction, vaccines, replacement of antibiotics

Food Safety: E. coli O157 vaccine, other veterinary biopharmaceutical products to address diseases in livestock which may have an effect on human health

Top products:

Animal Health:
Folltropin®-V, MAP®-5